CA2153720A1 - Expression systems utilizing autolyzing fusion proteins and a novel reducing polypeptide - Google Patents

Expression systems utilizing autolyzing fusion proteins and a novel reducing polypeptide

Info

Publication number
CA2153720A1
CA2153720A1 CA002153720A CA2153720A CA2153720A1 CA 2153720 A1 CA2153720 A1 CA 2153720A1 CA 002153720 A CA002153720 A CA 002153720A CA 2153720 A CA2153720 A CA 2153720A CA 2153720 A1 CA2153720 A1 CA 2153720A1
Authority
CA
Canada
Prior art keywords
sequence
polypeptide
protein
polynucleotide sequence
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002153720A
Other languages
English (en)
French (fr)
Inventor
Tohru Takahashi
Ryuta Koishi
Ichiro Kawashima
Nobufusa Serizawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP30380994A external-priority patent/JP3337178B2/ja
Application filed by Individual filed Critical Individual
Publication of CA2153720A1 publication Critical patent/CA2153720A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
CA002153720A 1994-07-13 1995-07-12 Expression systems utilizing autolyzing fusion proteins and a novel reducing polypeptide Abandoned CA2153720A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP16105394 1994-07-13
JP6-161053 1994-07-13
JP6-218392 1994-09-13
JP21839294 1994-09-13
JP30380994A JP3337178B2 (ja) 1994-07-13 1994-12-07 クローバーイエローベインウイルスプロテアーゼ
JP6-303809 1994-12-07

Publications (1)

Publication Number Publication Date
CA2153720A1 true CA2153720A1 (en) 1996-01-14

Family

ID=27321781

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002153720A Abandoned CA2153720A1 (en) 1994-07-13 1995-07-12 Expression systems utilizing autolyzing fusion proteins and a novel reducing polypeptide

Country Status (14)

Country Link
US (3) US5955072A (enExample)
EP (2) EP1251176A3 (enExample)
KR (1) KR100417026B1 (enExample)
CN (4) CN1090676C (enExample)
AU (1) AU696358B2 (enExample)
CA (1) CA2153720A1 (enExample)
CZ (2) CZ293582B6 (enExample)
FI (1) FI953422L (enExample)
HU (2) HUT72922A (enExample)
IL (1) IL114582A0 (enExample)
MX (1) MX9503070A (enExample)
NO (1) NO952763L (enExample)
NZ (1) NZ272561A (enExample)
TW (1) TW459046B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904539D0 (sv) * 1999-12-10 1999-12-10 Alphahelix Ab Method and device for the handling of samples and reagents
FR2824334B1 (fr) * 2001-05-03 2003-10-10 Coletica Procede pour tester une substance eventuellement active dans le domaine de la lipolyse et son utilisation principalement cosmetique
AU2003288474A1 (en) * 2002-06-24 2004-03-19 Exiqon A/S Methods and systems for detection and isolation of a nucleotide sequence
MX2007013725A (es) 2005-05-05 2008-04-09 Sensient Flavors Inc Produccion de beta-glucanos y mananos.
CN101595228A (zh) 2005-07-21 2009-12-02 艾博特公司 包括sorf构建体的多基因表达和使用多蛋白、前体蛋白和蛋白酶解的方法
US20100035300A1 (en) * 2006-02-27 2010-02-11 Wang Andrew H-J Producing a Target Protein Using Intramolecular Cleavage by TEV Protease
US9206431B2 (en) * 2007-09-27 2015-12-08 Academia Sinica Kit for producing recombinant tag-cleavable fusion proteins via at least two different expression vectors allow protein production in two different species host cells
US8501449B2 (en) 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
JP2013509188A (ja) * 2009-10-30 2013-03-14 アボット・ラボラトリーズ Ｓｏｒｆ構築物および複数の遺伝子発現

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3885431D1 (de) * 1987-12-23 1993-12-09 Boehringer Ingelheim Int Expression der viral kodierten Protease P2A des HRV2.
US5162601A (en) * 1989-11-22 1992-11-10 The Upjohn Company Plant potyvirus expression vector with a gene for protease
US6077694A (en) * 1990-09-21 2000-06-20 The United States Of America As Represented By The Department Of Health And Human Services Method for over-expression and rapid purification of biosynthetic proteins
RU2206611C2 (ru) * 1991-08-30 2003-06-20 Вертекс Фармасьютикалз Инкорпорейтед ФРАГМЕНТ ДНК, ПЛАЗМИДНЫЙ ВЕКТОР, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ПОЛИПЕПТИД, ОБЛАДАЮЩИЙ IL-1β ПРОТЕАЗНОЙ АКТИВНОСТЬЮ
AU1743795A (en) * 1994-02-03 1995-08-21 Scripps Research Institute, The A cassette to accumulate multiple proteins through synthesis of a self-processing polypeptide

Also Published As

Publication number Publication date
US5955072A (en) 1999-09-21
CN1126759A (zh) 1996-07-17
CZ180895A3 (en) 1996-02-14
AU2497095A (en) 1996-01-25
NZ272561A (en) 1997-03-24
FI953422A0 (fi) 1995-07-13
HU0202280D0 (enExample) 2002-09-28
NO952763L (no) 1996-01-15
HU9502114D0 (en) 1995-09-28
AU696358B2 (en) 1998-09-10
CN1385529A (zh) 2002-12-18
HUT72922A (en) 1996-06-28
CN1090676C (zh) 2002-09-11
CN1385532A (zh) 2002-12-18
CZ293582B6 (cs) 2004-06-16
NO952763D0 (no) 1995-07-12
TW459046B (en) 2001-10-11
EP1251176A3 (en) 2002-12-18
MX9503070A (es) 1997-01-31
KR100417026B1 (ko) 2004-05-17
US20030176688A1 (en) 2003-09-18
US6743611B2 (en) 2004-06-01
FI953422A7 (fi) 1996-01-14
FI953422L (fi) 1996-01-14
EP0700999A3 (en) 1997-04-16
US6307038B1 (en) 2001-10-23
EP1251176A2 (en) 2002-10-23
EP0700999A2 (en) 1996-03-13
CZ293745B6 (cs) 2004-07-14
CN1320689A (zh) 2001-11-07
IL114582A0 (en) 1995-11-27

Similar Documents

Publication Publication Date Title
CA2084514A1 (en) O-glycosylated ifn-alpha
WO1998033920A2 (en) Tissue factor pathway inhibitor-3
EP0699763B1 (en) Nucleic acid sequence encoding trypsin-like enzyme and process for producing the enzyme
US6307038B1 (en) Expression systems utilizing autolyzing fusion proteins and a novel reducing polypeptide
AU709054B2 (en) Compositions for the inhibition of TNF formation and uses thereof
CA2217450A1 (en) Use of an "immunodeficiency-virus suppressing lymphokine (isl)" to inhibit the replication of viruses, in particular of retroviruses
AU750170B2 (en) Caspase-14 polypeptides
CA2278349A1 (en) I-flice, a novel inhibitor of tumor necrosis factor receptor-1 and cd-95 induced apoptosis
NZ314127A (en) Coding sequence of the protease protein cyvv nia from clover yellow vein virus (potyvirus or plant rna virus) and uses thereof
HK1047601A (en) Expression systems utilizing autolyzing fusion proteins and a reducing polypeptide
HK1012024A (en) Expression systems utilizing autolyzing fusion proteins and a novel reducing polypeptide
RU2143491C1 (ru) Полинуклеотидная последовательность (варианты), полипептид (варианты), слитый белок, фармацевтическая композиция, моноклональное антитело, штамм гибридных культивируемых клеток
NZ509402A (en) Keratinocyte derived interferon
EP0814661A1 (en) UBIQUITIN CONJUGATING ENZYMES 7, 8 and 9
US5843693A (en) Assay method for screening for inhibitors of proTNF conversion
CA2174089A1 (en) Plasmodium falciparum ribonucleotide reductase, encoding dna, and inhibitors
US6586222B1 (en) Recombinant PR-3 and compositions thereof
US5945321A (en) Ubiquitin conjugating enzymes 7, 8 and 9
WO1997037022A1 (en) Human natural killer cell activating factor ii
JP3337178B2 (ja) クローバーイエローベインウイルスプロテアーゼ
AU717477B2 (en) Human cystatin E
WO1994016062A1 (en) Complement regulatory proteins of herpesvirus saimiri
WO1998028420A1 (en) Human parotid secretory protein
WO1998007862A9 (en) Chemokine beta-16
JPH08131178A (ja) 還元能を有するタンパク質、及び該タンパク質をコードするｄｎａ

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued